Floatz logo

Copanlisib

Endometrial Endometrioid Adenocarcinoma

NRG OncologySmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Endometrial Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Arimidex
Memorial Sloan Kettering Cancer Center
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Tirzepatide
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Tazemetostat
National Cancer Institute (NCI)
Phase 2CCC

View all 14 →

Same molecule, other indications

Copanlisib is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →